Stanford Cancer Center

# Hematology CRG

Click here to print this page (PDF)

29 January 2014

## Multiple Myeloma (MM)

**Newly Diagnosed**

Transplant Eligible

**HEMMYL0021**
Phase III RVD versus RVD plus auto SCT in newly diagnosed Multiple Myeloma

PI: Liedtke
Dana Farber Cancer Institute

**Relapsed/Refractory**

Non-Bortezomib Refractory

**HEMMYL0014**
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

PI: Liedtke
Stanford

Bortezomib Refractory

**HEMMYL0018**
Phase I/II Amrubicin in Combo w/ Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory MM

PI: Liedtke
Stanford

**KEY**

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study

*Please mark up a copy using black ink and fax changes to 725-9204*